Exact Mass: 633.3373612

Exact Mass Matches: 633.3373612

Found 133 metabolites which its exact mass value is equals to given mass value 633.3373612, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Golvatinib

N1-{2-fluoro-4-[(2-{[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

C33H37F2N7O4 (633.2874946)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor

   

PC(2:0/PGE2)

(2-{[(2R)-3-(acetyloxy)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3277812)


PC(2:0/PGE2) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/PGE2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(PGE2/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3277812)


PC(PGE2/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(PGE2/2:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/PGD2)

(2-{[(2R)-3-(acetyloxy)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3277812)


PC(2:0/PGD2) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/PGD2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(PGD2/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3277812)


PC(PGD2/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(PGD2/2:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

(2-{[(2R)-3-(acetyloxy)-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3277812)


PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H52NO11P (633.3277812)


PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   
   
   
   

(?)-(A-b)-14alpha-benzoyloxy-N-ethyl-3alpha,10beta,13beta,15alpha-tetrahydroxy-1alpha,6alpha,8beta,16beta,18-pentamethoxyaconitane

(?)-(A-b)-14alpha-benzoyloxy-N-ethyl-3alpha,10beta,13beta,15alpha-tetrahydroxy-1alpha,6alpha,8beta,16beta,18-pentamethoxyaconitane

C33H47NO11 (633.3148952)


   

cyclo-(Pro-Gly-Leu-Val-Pro-Ile-Gly)|gypsophin E

cyclo-(Pro-Gly-Leu-Val-Pro-Ile-Gly)|gypsophin E

C31H51N7O7 (633.3849776)


   
   

(3beta,4S,7alpha,9R,14alpha,15alpha,16beta)-3-acetoxy-4,9-epoxy-15-{[(2Z)-2-methylbut-2-enoyl]oxy}cevane-4,7,14,16,20-pentol

(3beta,4S,7alpha,9R,14alpha,15alpha,16beta)-3-acetoxy-4,9-epoxy-15-{[(2Z)-2-methylbut-2-enoyl]oxy}cevane-4,7,14,16,20-pentol

C34H51NO10 (633.3512786)


   
   
   

Asp Lys Trp Trp

(3S)-3-amino-3-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}pentyl]carbamoyl}propanoic acid

C32H39N7O7 (633.2910824)


   

Asp Trp Lys Trp

(3S)-3-amino-3-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pentyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C32H39N7O7 (633.2910824)


   

Asp Trp Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C32H39N7O7 (633.2910824)


   

Phe Arg Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C27H47N13O5 (633.3822931999999)


   

Lys Asp Trp Trp

(3S)-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-3-[(2S)-2,6-diaminohexanamido]propanoic acid

C32H39N7O7 (633.2910824)


   

Lys Trp Asp Trp

(3S)-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-3-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]propanoic acid

C32H39N7O7 (633.2910824)


   

Lys Trp Trp Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]butanedioic acid

C32H39N7O7 (633.2910824)


   

Arg Phe Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C27H47N13O5 (633.3822931999999)


   

Arg Arg Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C27H47N13O5 (633.3822931999999)


   

Arg Arg Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C27H47N13O5 (633.3822931999999)


   

Arg Ser Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O6 (633.3023154)


   

Arg Trp Ser Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O6 (633.3023154)


   

Arg Trp Trp Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C31H39N9O6 (633.3023154)


   

Ser Arg Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O6 (633.3023154)


   

Ser Trp Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O6 (633.3023154)


   

Ser Trp Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C31H39N9O6 (633.3023154)


   

Trp Asp Lys Trp

(3S)-3-{[(1S)-5-amino-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pentyl]carbamoyl}-3-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]propanoic acid

C32H39N7O7 (633.2910824)


   

Trp Asp Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carboxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C32H39N7O7 (633.2910824)


   

Trp Lys Asp Trp

(3S)-3-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C32H39N7O7 (633.2910824)


   

Trp Lys Trp Asp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]butanedioic acid

C32H39N7O7 (633.2910824)


   

Trp Arg Ser Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O6 (633.3023154)


   

Trp Arg Trp Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C31H39N9O6 (633.3023154)


   

Trp Ser Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O6 (633.3023154)


   

Trp Ser Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C31H39N9O6 (633.3023154)


   

Trp Trp Asp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-carboxypropanamido]hexanoic acid

C32H39N7O7 (633.2910824)


   

Trp Trp Lys Asp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]butanedioic acid

C32H39N7O7 (633.2910824)


   

Trp Trp Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C31H39N9O6 (633.3023154)


   

Trp Trp Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C31H39N9O6 (633.3023154)


   

PKOHA-PC

1-hexadecanoyl-2-(4,7-dioxo-5E-heptenoyl)-sn-glycero-3-phosphocholine

C31H56NO10P (633.3641646)


   

OKHdiA-PE

1-(9Z-octadecenoyl)-2-(4-oxo-6-carboxy-5E-hexenoyl)-sn-glycero-3-phosphoethanolamine

C30H52NO11P (633.3277812)


   

OHOOA-PE

1-(9Z-octadecenoyl)-2-(5-hydroxy-8-oxo-6E-octenoyl)-sn-glycero-3-phosphoethanolamine

C31H56NO10P (633.3641646)


   
   

Golvatinib

Golvatinib (E7050)

C33H37F2N7O4 (633.2874946)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor

   
   
   
   
   

PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PC(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C30H52NO11P (633.3277812)


   

PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)

PC(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)

C30H52NO11P (633.3277812)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoate

C35H56NO7P (633.3794196)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

2-amino-3-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

2-amino-3-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

2-amino-3-[[3-heptanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-heptanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

2-amino-3-[[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C31H56NO10P (633.3641646)


   

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]propanamide

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]propanamide

C30H51NO13 (633.3360236000001)


   

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]butanamide

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]butanamide

C30H51NO13 (633.3360236000001)


   

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadeca-4,8,12-trien-2-yl]acetamide

N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadeca-4,8,12-trien-2-yl]acetamide

C30H51NO13 (633.3360236000001)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(1s,2s,3s,4s,5s,8s,9r,10r,11s,14s,16r,17s,18s,19s)-2,19-bis(acetyloxy)-3-hydroxy-5-methyl-4-{[(2s)-2-methylbutanoyl]oxy}-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

(1s,2s,3s,4s,5s,8s,9r,10r,11s,14s,16r,17s,18s,19s)-2,19-bis(acetyloxy)-3-hydroxy-5-methyl-4-{[(2s)-2-methylbutanoyl]oxy}-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

C36H43NO9 (633.2937668000001)


   

aconifine; 8-o-de-ac,8-et ether,n-de-et,n-me

NA

C33H47NO11 (633.3148952)


{"Ingredient_id": "HBIN014570","Ingredient_name": "aconifine; 8-o-de-ac,8-et ether,n-de-et,n-me","Alias": "NA","Ingredient_formula": "C33H47NO11","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7200","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1r,2s,3s,4s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-2,19-bis(acetyloxy)-3-hydroxy-5-methyl-4-[(2-methylbutanoyl)oxy]-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

(1r,2s,3s,4s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-2,19-bis(acetyloxy)-3-hydroxy-5-methyl-4-[(2-methylbutanoyl)oxy]-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

C36H43NO9 (633.2937668000001)


   

(1s,2r,3r,4r,5r,6s,7s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-5,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

(1s,2r,3r,4r,5r,6s,7s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-5,7,8,14-tetrahydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H47NO11 (633.3148952)


   

(1s,2r,3s,4r,5s,8s,9r,10r,11s,14s,16r,17s,18s,19s)-2,19-bis(acetyloxy)-4-hydroxy-5-methyl-3-{[(2r)-2-methylbutanoyl]oxy}-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

(1s,2r,3s,4r,5s,8s,9r,10r,11s,14s,16r,17s,18s,19s)-2,19-bis(acetyloxy)-4-hydroxy-5-methyl-3-{[(2r)-2-methylbutanoyl]oxy}-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

C36H43NO9 (633.2937668000001)


   

3-[(13s)-5,6,9,12,15,16-hexahydroxy-2-oxo-7-[(2e,4e,6e)-pentadeca-2,4,6-trien-1-yl]-3h,3ah,6h,7h,10h,13h,16h,16ah-furo[3,2-l]1,4,7,11-tetraazacyclopentadecan-13-yl]propanimidic acid

3-[(13s)-5,6,9,12,15,16-hexahydroxy-2-oxo-7-[(2e,4e,6e)-pentadeca-2,4,6-trien-1-yl]-3h,3ah,6h,7h,10h,13h,16h,16ah-furo[3,2-l]1,4,7,11-tetraazacyclopentadecan-13-yl]propanimidic acid

C31H47N5O9 (633.3373612)


   

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-16-methoxy-2-oxa-6,9,12-triazatricyclo[13.3.1.0³,⁷]nonadeca-1(18),8,11,13,15(19),16-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-[(hydroxymethylidene)amino]-3-methylbutanimidic acid

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-16-methoxy-2-oxa-6,9,12-triazatricyclo[13.3.1.0³,⁷]nonadeca-1(18),8,11,13,15(19),16-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-[(hydroxymethylidene)amino]-3-methylbutanimidic acid

C34H43N5O7 (633.3162328000001)


   

(1r,2s,3s,4s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-2,19-bis(acetyloxy)-4-hydroxy-5-methyl-3-[(2-methylbutanoyl)oxy]-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

(1r,2s,3s,4s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-2,19-bis(acetyloxy)-4-hydroxy-5-methyl-3-[(2-methylbutanoyl)oxy]-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-yl benzoate

C36H43NO9 (633.2937668000001)


   

(3r,6s,9s,12s,17as)-9-benzyl-1,4,10-trihydroxy-6-[(4-hydroxyphenyl)methyl]-3-isopropyl-8-methyl-12-(2-methylpropyl)-3h,6h,9h,12h,15h,16h,17h,17ah-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecane-7,13-dione

(3r,6s,9s,12s,17as)-9-benzyl-1,4,10-trihydroxy-6-[(4-hydroxyphenyl)methyl]-3-isopropyl-8-methyl-12-(2-methylpropyl)-3h,6h,9h,12h,15h,16h,17h,17ah-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecane-7,13-dione

C35H47N5O6 (633.3526162)